Third Rock Ventures, a venture capital firm, and Sofinnova Investments, a healthcare investment firm, led a $190m round in Marea Therapeutics, a clinical-stage biotechnology company, with participation from Forbion, Perceptive Xontogeny Venture Fund, venBio, Alpha Wave Global, Omega Funds and Surveyor Capital. “With initial clinical validation, world-class scientific founders and investors, and an experienced board and leadership team, Marea is poised to become a premier cardiometabolic disease company,”“We aim to accelerate a new generation of medicines, including MAR001, that treat key unaddressed drivers of cardiometabolic disease, potentially providing important new therapeutic options for millions of patients,” Jeffrey Tong, Third Rock Ventures Board Member and Partner.